Recruiting

Testing a new medication for nerve tumors caused by neurofibromatosis type 1

Plain-English translation of NCT07407803 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new drug called TQ-B3234 to see if it can shrink plexiform neurofibromas—tumors that grow on nerves—in people with neurofibromatosis type 1 (NF1) who are not able to have surgery. Half of the participants will take the medication daily, and half will take a placebo (a pill with no active ingredient) so researchers can fairly compare how well this treatment works.

Plexiform neurofibromas caused by NF1 can cause pain and other serious problems, but surgery isn't always possible or safe for every patient. This medication is being tested as a new option to help shrink these tumors without surgery.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with neurofibromatosis type 1 with plexiform neurofibromas that cannot be surgically removed
you have at least one tumor that measures 3 centimeters or larger
you are in good enough health to participate (ECOG performance status 0–1)
you are willing to use effective birth control during the study and for 6 months afterward (if applicable)
your blood work and other lab tests meet the study requirements

You likely don't qualify if…

you have or are suspected to have cancer related to your tumors (such as malignant glioma or MPNST)
you have been diagnosed with another cancer within the past 5 years
you have serious problems swallowing or absorbing oral medications, or have had major bowel surgery
you have had blood clots or stroke-like events in the past 6 months
you have had major eye problems such as retinal vein occlusion, glaucoma, or high eye pressure

What participation looks like

If you join this study, you will take one capsule of the medication (or placebo) by mouth once every day for 4-week cycles. You'll visit the research center regularly so doctors can measure your tumors using MRI scans and check your health with blood tests and physical exams. The study focuses on whether the treatment shrinks tumors after 24 weeks, though you may continue longer if it's helping you.

AI-generated summary from trial data · Aug 22, 2026 · Not medical advice

Trial locations(29 sites)

China

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui

Peking Union Medical College Hospital, Beijing, Beijing Municipality

Xuanwu Hospital Capital Medical University, Beijing, Beijing Municipality

Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality

Peking University Third Hospital, Beijing, Beijing Municipality